In their own words

Stories from patients with non-invasive, ductal carcinoma in situ (DCIS) breast cancer

Do you know your Oncotype DX Breast DCIS Score® result?

Meet Jen — DCIS Score result: 42

Jen’s story

"For me, the Oncotype DX DCIS test was a key piece of evidence, which confirmed my decision to have a double mastectomy. I want every patient to have access to this test and the peace of mind that comes with it."

A busy mother of 2 and active community volunteer, Jen is passionate about making other patients aware of the Oncotype DX Breast DCIS Score® test, so that they too can base their treatment decisions on the underlying biology of their individual tumors.

Throughout her ductal carcinoma in situ (DCIS) treatment journey, Jen was lucky to have support from her Yale Women's Crew teammates, and her close friends and family–whom she credits for introducing her to the Oncotype DX Breast DCIS Score® test. Upon sharing her DCIS diagnosis with her family, one of her relatives, a pathologist at John Hopkins, suggested she speak to her doctor about the Oncotype DX® test for DCIS patients, as he felt it would be an important data point as she considered treatment options, and her doctors agreed.

"The Oncotype DX DCIS test was a critical piece of data that helped keep me moving forward in my own process. Being given personalized information specific to my tumor allowed me to move ahead confidently."

Learn how the DCIS Score test can help individualize your treatment

Learn about the DCIS Score testing process

In their own words: Stories  from patients with non-invasive DCIS breast cancer

See FAQs and videos  about the DCIS Score test



financial responsibility for DCIS Score test when Medicare fee-for-service (FFS) coverage criteria are met

Medicare Advantage, which is provided by commercial insurance companies, may have different financial responsibility compared to Medicare FFS.


Learn about costs, coverage, and how Exact Sciences can help